In C2C12 myotubes, AdipoRon increased AMPK phosphorylation, and AdipoR1 knockdown attenuated the response. It did not further increase AMPK phosphorylation at a maximal adiponectin concentration, indicating a context-dependent response ceiling. [1]
In stimulated BV2 microglia, AdipoRon reduced inflammatory cytokine transcription, IL-6/TNF-α secretion and NO production across a 1–50 μM concentration series. The findings describe cell-assay readouts; viability-normalized anti-inflammatory activity was not established by these assays. [2]
AdipoRon binding to human adiponectin receptors
Biochemical assay · Purified human AdipoR1 and AdipoR2 reconstituted in liposomes and immobilized on an SA sensor chip [1]
Saturable receptor binding was measured by surface plasmon resonance. A rhodopsin receptor control was reported as nonreactive in SI. These affinity endpoints are not cellular EC50 or IC50 values.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.49–31.25 μM
- Method
- Surface plasmon resonance (BIAcore X100)
- Reported limits
- Binding exposure duration, replicate n and compound solvent are not specified in the adopted figure caption/relevant extracted binding-method passage.
Methods and source locations
Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon
Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.
Figure 1a,j,k and caption; main receptor-binding paragraph; SI Binding assays
Equilibrium binding to AdipoR1: SPR equilibrium fit — Figure 1j; SI Binding assays
Equilibrium binding to AdipoR2: SPR equilibrium fit — Figure 1k; SI Binding assays
AMPK phosphorylation and receptor dependence in myotubes
Cell-based study · Differentiated C2C12 mouse myotubes [1]
AdipoRon increased AMPK phosphorylation; AdipoR1 siRNA reduced the response relative to unrelated siRNA. Compound 165073 was an inactive comparator and AICAR served as a mechanistically distinct positive control. AdipoRon did not further raise phosphorylation in the presence of maximal adiponectin.
Literature-Reported Treatment Conditions
- Treatment concentration
- Dose response: 0.05–50 μM; siRNA comparison: 25 μM
- Exposure duration
- 5 min for AdipoRon exposure
- Method
- Immunoblot of phosphorylated AMPK normalized to total AMPK
- Reported limits
- Compound vehicle is not identified in the adopted caption/relevant extracted methods. n=4 for Figure 1b,c,e; n=3 for Figure 1d; values mean ± s.e.m., not necessarily independent biological preparations.
Methods and source locations
Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon
Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.
Figure 1b–e and caption; Methods Summary Studies with C2C12 cells; SI RNA interference and immunoblotting
AMPK phosphorylation and AdipoR1-siRNA attenuation: Immunoblot; unrelated siRNA control — Figure 1b,c; SI RNA interference
Additional AMPK phosphorylation with maximal adiponectin: Immunoblot; adiponectin-alone comparison — Figure 1e and caption
Inflammatory readouts in stimulated microglia
Cell-based study · Murine BV2 microglial cells stimulated with purified lipopolysaccharide [2]
Compared with stimulated vehicle controls, AdipoRon lowered cytokine transcription and IL-6/TNF-α secretion and reduced NO production. Responses varied by endpoint and concentration; a universal significant effect at every dose is not established.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 10 and 50 μM; 0 μM vehicle comparator
- Exposure duration
- 1 h pretreatment; subsequent readouts at 4 h (mRNA), 6 h (secreted cytokines), or 24 h (NO)
- Method
- qRT-PCR, ELISA and colorimetric NO assay
- Vehicle
- DMSO; Methods 2.6 identifies 1% DMSO control
- Reported limits
- Figure 7 reports n=3, mean ± SEM, without establishing independent biological versus technical replication. A viability-normalized response is not established in these adopted assays.
Methods and source locations
Compound reported in the paper: AdipoRon; Compound label in the paper: AdipoRon
Applies to the named research compound and stated experimental model; it does not validate a catalog lot or establish clinical efficacy.
Methods 2.4,2.6,2.9–2.12; Results 3.5; Figure 7A–F and caption
Cytokine transcription, cytokine secretion and NO production: Figure 7: transcription relative to Actin; ELISA for IL-6 and TNF-α; NO assay; one-way ANOVA with Bonferroni tests — Figure 7A–F and caption; Results 3.5